Kiyoshi Takeda
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Kiyoshi Takeda has a total of 383 co-authors. Here are the top co-authors by number of shared publications:
Hisako Kayama
Laboratory of Immune Regulation, Department of Microbiology and Immunology, Graduate School of Medicine, University of Osaka, Suita, Osaka, Japan; Institute for Advanced Co-Creation Studies, University of Osaka, Suita, Osaka, Japan; WPI Immunology Frontier Research Center, University of Osaka, Suita, Osaka, Japan
30 shared publicationsRyu Okumura
Department of Microbiology and Immunology, Graduate School of Medicine, Osaka University, Suita, Japan
23 shared publicationsMasahiro Yamamoto
Laboratory of Immunoparasitology, WPI Immunology Frontier Research Center, Osaka University, Osaka, Japan
18 shared publications- Daisuke Okuzaki
Laboratory for Human Immunology (Single Cell Genomics), WPI Immunology Frontier Research Center, The University of Osaka, Suita 565-0871, Japan
15 shared publications - Hisako Kayama
Laboratory of Immune Regulation, Department of Microbiology and Immunology, Graduate School of Medicine, The University of Osaka , Suita, Osaka 565-0871
15 shared publications Daisuke Motooka
WPI Immunology Frontier Research Center, The University of Osaka , Suita, Osaka 565-0871
13 shared publications
Latest Publications
- 13 May 2026
- Published by Oxford University Press (OUP) in International Immunology
- Vol. 38 (10) , 610-625
The interleukin-10/interleukin-10Rα axis in fibroblasts limits large intestinal pathology by suppressing Type I interferon signaling
Recent studies identified that the dysregulation of fibroblast activity, in addition to impairment in epithelial integrity and uncontrolled immune response, is implicated in the pathogenesis of inflammatory bowel disease (IBD). The anti-inflammatory cytokine interleukin (IL)-10 and its receptors IL-10Rα and IL-10Rβ have IBD-associated single nucleotide polymorphisms. In the intestine, IL-10 signaling is essential for maintaining an anti-inflammatory state of myeloid cells and inducing regulatory T cells, thereby preventing intestinal inflammation linked to IBD development. However, its impact on the physiology and pathophysiology of intestinal fibroblasts is poorly understood. Here, we show that Il10ra deficiency leads to increased expression of a subset of genes in colonic fibroblasts, most of which are associated with the Type I interferon (IFN) and Type II IFN signaling pathways. In addition, Pdgfra-cre; Il10raf/f mice aged 16 weeks or older develop chronic spontaneous colitis and subsequent fibrosis accompanied by enhanced infiltration by myeloid cells and effector CD4+ T cells in the lamina propria of the colon. Moreover, Pdgfra-cre; Il10raf/f mice at 12 weeks of age exhibit more severe clinical symptoms than those of Il10raf/f mice during dextran sodium sulfate–induced colitis that can be suppressed by the administration of anti-IFNAR1 antibody but not anti-IFNGR1 antibody. Therefore, inhibition of the Type I IFN pathway via IL-10Rα signaling in fibroblasts is one of the IL-10–dependent mechanisms underlying the prevention of large intestinal pathology.
- 13 May 2026
- Published by Oxford University Press (OUP) in International Immunology
- Vol. 38 (10) , 610-625
The interleukin-10/interleukin-10Rα axis in fibroblasts limits large intestinal pathology by suppressing Type I interferon signaling
Recent studies identified that the dysregulation of fibroblast activity, in addition to impairment in epithelial integrity and uncontrolled immune response, is implicated in the pathogenesis of inflammatory bowel disease (IBD). The anti-inflammatory cytokine interleukin (IL)-10 and its receptors IL-10Rα and IL-10Rβ have IBD-associated single nucleotide polymorphisms. In the intestine, IL-10 signaling is essential for maintaining an anti-inflammatory state of myeloid cells and inducing regulatory T cells, thereby preventing intestinal inflammation linked to IBD development. However, its impact on the physiology and pathophysiology of intestinal fibroblasts is poorly understood. Here, we show that Il10ra deficiency leads to increased expression of a subset of genes in colonic fibroblasts, most of which are associated with the Type I interferon (IFN) and Type II IFN signaling pathways. In addition, Pdgfra-cre; Il10raf/f mice aged 16 weeks or older develop chronic spontaneous colitis and subsequent fibrosis accompanied by enhanced infiltration by myeloid cells and effector CD4+ T cells in the lamina propria of the colon. Moreover, Pdgfra-cre; Il10raf/f mice at 12 weeks of age exhibit more severe clinical symptoms than those of Il10raf/f mice during dextran sodium sulfate–induced colitis that can be suppressed by the administration of anti-IFNAR1 antibody but not anti-IFNGR1 antibody. Therefore, inhibition of the Type I IFN pathway via IL-10Rα signaling in fibroblasts is one of the IL-10–dependent mechanisms underlying the prevention of large intestinal pathology.
- 6 February 2026
- Published by Elsevier
- Vol. 220, 339-359
Microbiota-derived metabolites in intestinal immune disorders
- 6 February 2026
- Published by Elsevier
- Vol. 220, 339-359
Microbiota-derived metabolites in intestinal immune disorders
- Open Access
- 30 December 2025
- Published by Elsevier in Mucosal Immunology
- Vol. 19 (2) , 1783-1798
Single-cell transcriptome analysis reveals the association between ketone body synthesis and morphogenic profile of intestinal epithelia in neonatal mice
- 30 December 2025
- Published by Elsevier in Mucosal Immunology
- Vol. 19 (2) , 1783-1798
Open AccessSingle-cell transcriptome analysis reveals the association between ketone body synthesis and morphogenic profile of intestinal epithelia in neonatal mice
- Open Access
- 4 September 2025
- Published by Rockefeller University Press in Journal of Experimental Medicine
- Vol. 222 (11)
Multi-omics uncovers transcriptional programs of gut-resident memory CD4+ T cells in Crohn’s disease
Tissue-resident memory T cells (TRM) remain in nonlymphatic barrier tissues for extended periods and are deeply involved in immune memory at the site of inflammation. Here, we employed multilayered single-cell analytic approaches including chromatin, gene, and protein profiling to characterize a unique CD4+ TRM subset present in the inflamed gut mucosa of Crohn’s disease patients. We identified two key transcription factors, RUNX2 and BHLHE40, as regulators of pathologically relevant CD4+ TRM. These transcriptional regulators work together to induce distinct cellular properties of disease-specific TRM, such as cytotoxicity, T helper 1–effector activity, and tissue retention. Downregulation of RUNX2 and BHLHE40 in patient-derived gut CD4+ T cells resulted in the mitigation of the pathogenic phenotype of these cells. Conversely, the ectopic overexpression of both transcription factors in healthy donor–derived CD4+ T cells drove IFN-γ pathways and enhanced tissue residency. Our findings illuminate the transcriptional programs driving disease-specific T cell formation in Crohn’s disease.
- 4 September 2025
- Published by Rockefeller University Press in Journal of Experimental Medicine
- Vol. 222 (11)
Open AccessMulti-omics uncovers transcriptional programs of gut-resident memory CD4+ T cells in Crohn’s disease
Tissue-resident memory T cells (TRM) remain in nonlymphatic barrier tissues for extended periods and are deeply involved in immune memory at the site of inflammation. Here, we employed multilayered single-cell analytic approaches including chromatin, gene, and protein profiling to characterize a unique CD4+ TRM subset present in the inflamed gut mucosa of Crohn’s disease patients. We identified two key transcription factors, RUNX2 and BHLHE40, as regulators of pathologically relevant CD4+ TRM. These transcriptional regulators work together to induce distinct cellular properties of disease-specific TRM, such as cytotoxicity, T helper 1–effector activity, and tissue retention. Downregulation of RUNX2 and BHLHE40 in patient-derived gut CD4+ T cells resulted in the mitigation of the pathogenic phenotype of these cells. Conversely, the ectopic overexpression of both transcription factors in healthy donor–derived CD4+ T cells drove IFN-γ pathways and enhanced tissue residency. Our findings illuminate the transcriptional programs driving disease-specific T cell formation in Crohn’s disease.
- 18 July 2025
- Published by American Association for the Advancement of Science (AAAS) in Science Immunology
- Vol. 10 (109) , eadm6843
OTUD3 prevents ulcerative colitis by inhibiting microbiota-mediated STING activation
Ulcerative colitis (UC) develops through a complicated interaction between the host and microbiota. Intestinal fibroblasts are believed to play crucial roles in the pathogenesis of UC, but the influence of the host-microbiota interaction on the pathophysiology of intestinal fibroblasts remains poorly understood. Here, we demonstrate that OTU deubiquitinase 3 (OTUD3) suppresses pathologic activation of fibroblasts exposed to microbial cyclic GMP-AMP (3′3’-cGAMP) in the colon by deubiquitinating stimulator of interferon genes (STING). Mice harboring a UC risk missense variant in the Otud3 gene showed pathological features of UC in the colon after transplantation of a fecal microbiota with the potential to produce excessive cGAMP from patients with UC. Collectively, these results highlight a mechanism of the interaction between OTUD3 in host fibroblasts and STING-activating microbiota in UC development.
- 18 July 2025
- Published by American Association for the Advancement of Science (AAAS) in Science Immunology
- Vol. 10 (109) , eadm6843
OTUD3 prevents ulcerative colitis by inhibiting microbiota-mediated STING activation
Ulcerative colitis (UC) develops through a complicated interaction between the host and microbiota. Intestinal fibroblasts are believed to play crucial roles in the pathogenesis of UC, but the influence of the host-microbiota interaction on the pathophysiology of intestinal fibroblasts remains poorly understood. Here, we demonstrate that OTU deubiquitinase 3 (OTUD3) suppresses pathologic activation of fibroblasts exposed to microbial cyclic GMP-AMP (3′3’-cGAMP) in the colon by deubiquitinating stimulator of interferon genes (STING). Mice harboring a UC risk missense variant in the Otud3 gene showed pathological features of UC in the colon after transplantation of a fecal microbiota with the potential to produce excessive cGAMP from patients with UC. Collectively, these results highlight a mechanism of the interaction between OTUD3 in host fibroblasts and STING-activating microbiota in UC development.
- 8 January 2025
- Published by Oxford University Press (OUP) in International Immunology
- Vol. 37 (4) , 235-250
Intestinal Foxl1+ cell-derived CXCL12 maintains epithelial homeostasis by modulating cellular metabolism
Several mesenchymal cell populations are known to regulate intestinal stem cell (ISC) self-renewal and differentiation. However, the influences of signaling mediators derived from mesenchymal cells other than ISC niche factors on epithelial homeostasis remain poorly understood. Here, we show that host and microbial metabolites, such as taurine and gamma-aminobutyric acid (GABA), act on PDGFRαhigh Foxl1high sub-epithelial mesenchymal cells to regulate their transcription. In addition, we found that CXC chemokine ligand 12 (CXCL12) produced from Foxl1high sub-epithelial mesenchymal cells induces epithelial cell cycle arrest through modulation of the mevalonate–cholesterol synthesis pathway, which suppresses tumor progression in ApcMin/+ mice. We identified that Foxl1high sub-epithelial cells highly express CXCL12 among colonic mesenchymal cells. Foxl1-cre; Cxcl12f/f mice showed an increased number of Ki67+ colonic epithelial cells. CXCL12-induced Ca2+ mobilization facilitated phosphorylation of AMPK in intestinal epithelial cells, which inhibits the maturation of sterol regulatory element-binding proteins (SREBPs) that are responsible for mevalonate pathway activation. Furthermore, Cxcl12 deficiency in Foxl1-expressing cells promoted tumor development in the small and large intestines of ApcMin/+ mice. Collectively, these results demonstrate that CXCL12 secreted from Foxl1high mesenchymal cells manipulates intestinal epithelial cell metabolism, which links to the prevention of tumor progression in ApcMin/+ mice.
- 8 January 2025
- Published by Oxford University Press (OUP) in International Immunology
- Vol. 37 (4) , 235-250
Intestinal Foxl1+ cell-derived CXCL12 maintains epithelial homeostasis by modulating cellular metabolism
Several mesenchymal cell populations are known to regulate intestinal stem cell (ISC) self-renewal and differentiation. However, the influences of signaling mediators derived from mesenchymal cells other than ISC niche factors on epithelial homeostasis remain poorly understood. Here, we show that host and microbial metabolites, such as taurine and gamma-aminobutyric acid (GABA), act on PDGFRαhigh Foxl1high sub-epithelial mesenchymal cells to regulate their transcription. In addition, we found that CXC chemokine ligand 12 (CXCL12) produced from Foxl1high sub-epithelial mesenchymal cells induces epithelial cell cycle arrest through modulation of the mevalonate–cholesterol synthesis pathway, which suppresses tumor progression in ApcMin/+ mice. We identified that Foxl1high sub-epithelial cells highly express CXCL12 among colonic mesenchymal cells. Foxl1-cre; Cxcl12f/f mice showed an increased number of Ki67+ colonic epithelial cells. CXCL12-induced Ca2+ mobilization facilitated phosphorylation of AMPK in intestinal epithelial cells, which inhibits the maturation of sterol regulatory element-binding proteins (SREBPs) that are responsible for mevalonate pathway activation. Furthermore, Cxcl12 deficiency in Foxl1-expressing cells promoted tumor development in the small and large intestines of ApcMin/+ mice. Collectively, these results demonstrate that CXCL12 secreted from Foxl1high mesenchymal cells manipulates intestinal epithelial cell metabolism, which links to the prevention of tumor progression in ApcMin/+ mice.
- Open Access
- 1 January 2025
- Published by AMED iD3 Catalyst Unit in Translational and Regulatory Sciences
- Vol. 7 (2) , 94-102
Intestinal immune responses driven by gut microbial metabolite-GPCR signaling and advances in human in vitro models
Intestinal metabolites produced by gut microbiota have an important function as signaling molecules for host intestinal immune cells and mediate their effects via G protein-coupled receptors (GPCRs). Recently, an increasing number of novel gut microbial metabolite–GPCR axes have been identified, revealing dynamic and intricate interactions between the microbiota, their metabolites, and the host immune system. These discoveries have highlighted the importance of metabolic communication in regulating intestinal immune homeostasis and the development of various inflammatory and infectious diseases. At the same time, significant advances have been made in developing sophisticated human in vitro models, including organoid and co-culture systems, which have enabled the more precise elucidation of these axes and their underlying mechanisms, overcoming previous technical limitations associated with animal models or traditional cell lines. In this review, we focus on the pyruvate–GPR31 axis, which we have characterized as a key mechanism for maintaining intestinal homeostasis, and provide an overview of immune responses mediated by gut microbial metabolite–GPCR signaling. We also highlight recent progress in the development of innovative co-culture models—particularly those utilizing human cells—that have proven valuable in dissecting the functional impact of gut microbial metabolites on the human immune system.
- 1 January 2025
- Published by AMED iD3 Catalyst Unit in Translational and Regulatory Sciences
- Vol. 7 (2) , 94-102
Open AccessIntestinal immune responses driven by gut microbial metabolite-GPCR signaling and advances in human in vitro models
Intestinal metabolites produced by gut microbiota have an important function as signaling molecules for host intestinal immune cells and mediate their effects via G protein-coupled receptors (GPCRs). Recently, an increasing number of novel gut microbial metabolite–GPCR axes have been identified, revealing dynamic and intricate interactions between the microbiota, their metabolites, and the host immune system. These discoveries have highlighted the importance of metabolic communication in regulating intestinal immune homeostasis and the development of various inflammatory and infectious diseases. At the same time, significant advances have been made in developing sophisticated human in vitro models, including organoid and co-culture systems, which have enabled the more precise elucidation of these axes and their underlying mechanisms, overcoming previous technical limitations associated with animal models or traditional cell lines. In this review, we focus on the pyruvate–GPR31 axis, which we have characterized as a key mechanism for maintaining intestinal homeostasis, and provide an overview of immune responses mediated by gut microbial metabolite–GPCR signaling. We also highlight recent progress in the development of innovative co-culture models—particularly those utilizing human cells—that have proven valuable in dissecting the functional impact of gut microbial metabolites on the human immune system.
- Top Cited PapersOpen Access
- 26 November 2024
- Published by Springer Nature in Seminars in Immunopathology
- Vol. 47 (1) , 1-16
The role of the mucosal barrier system in maintaining gut symbiosis to prevent intestinal inflammation
In the intestinal tract, where numerous intestinal bacteria reside, intestinal epithelial cells produce and release various antimicrobial molecules that form a complex barrier on the mucosal surface. These barrier molecules can be classified into two groups based on their functions: those that exhibit bactericidal activity through chemical reactions, such as antimicrobial peptides, and those that physically hinder bacterial invasion, like mucins, which lack bactericidal properties. In the small intestine, where Paneth cells specialize in producing antimicrobial peptides, the chemical barrier molecules primarily inhibit bacterial growth. In contrast, in the large intestine, where Paneth cells are absent, allowing bacterial growth, the primary defense mechanism is the physical barrier, mainly composed of mucus, which controls bacterial movement and prevents their invasion of intestinal tissues. The expression of these barrier molecules is regulated by metabolites produced by bacteria in the intestinal lumen and cytokines produced by immune cells in the lamina propria. This regulation establishes a defense mechanism that adapts to changes in the intestinal environment, such as alterations in gut microbial composition and the presence of pathogenic bacterial infections. Consequently, when the integrity of the gut mucosal barrier is compromised, commensal bacteria and pathogenic microorganisms from outside the body can invade intestinal tissues, leading to conditions such as intestinal inflammation, as observed in cases of inflammatory bowel disease.
- 26 November 2024
- Published by Springer Nature in Seminars in Immunopathology
- Vol. 47 (1) , 1-16
Top Cited PapersOpen AccessThe role of the mucosal barrier system in maintaining gut symbiosis to prevent intestinal inflammation
In the intestinal tract, where numerous intestinal bacteria reside, intestinal epithelial cells produce and release various antimicrobial molecules that form a complex barrier on the mucosal surface. These barrier molecules can be classified into two groups based on their functions: those that exhibit bactericidal activity through chemical reactions, such as antimicrobial peptides, and those that physically hinder bacterial invasion, like mucins, which lack bactericidal properties. In the small intestine, where Paneth cells specialize in producing antimicrobial peptides, the chemical barrier molecules primarily inhibit bacterial growth. In contrast, in the large intestine, where Paneth cells are absent, allowing bacterial growth, the primary defense mechanism is the physical barrier, mainly composed of mucus, which controls bacterial movement and prevents their invasion of intestinal tissues. The expression of these barrier molecules is regulated by metabolites produced by bacteria in the intestinal lumen and cytokines produced by immune cells in the lamina propria. This regulation establishes a defense mechanism that adapts to changes in the intestinal environment, such as alterations in gut microbial composition and the presence of pathogenic bacterial infections. Consequently, when the integrity of the gut mucosal barrier is compromised, commensal bacteria and pathogenic microorganisms from outside the body can invade intestinal tissues, leading to conditions such as intestinal inflammation, as observed in cases of inflammatory bowel disease.
- Open Access
- 12 November 2024
- Published by Springer Nature in Inflammation and Regeneration
- Vol. 44 (1) , 1-2
The new era for the research on the regulation of microorganism-induced inflammation
- 12 November 2024
- Published by Springer Nature in Inflammation and Regeneration
- Vol. 44 (1) , 1-2
Open AccessThe new era for the research on the regulation of microorganism-induced inflammation
- 18 December 2023
- Published by Oxford University Press (OUP) in International Immunology
- Vol. 36 (4) , 155-166
The UDP-glucose/P2Y14 receptor axis promotes eosinophil-dependent large intestinal inflammation
Ulcerative colitis (UC) is a chronic disorder of the large intestine with inflammation and ulceration. The incidence and prevalence of UC have been rapidly increasing worldwide, but its etiology remains unknown. In patients with UC, the accumulation of eosinophils in the large intestinal mucosa is associated with increased disease activity. However, the molecular mechanism underlying the promotion of intestinal eosinophilia in patients with UC remains poorly understood. Here, we show that uridine diphosphate (UDP)-glucose mediates the eosinophil-dependent promotion of colonic inflammation via the purinergic receptor P2Y14. The expression of P2RY14 mRNA was upregulated in the large intestinal mucosa of patients with UC. The P2Y14 receptor ligand UDP-glucose was increased in the large intestinal tissue of mice administered dextran sodium sulfate (DSS). In addition, P2ry14 deficiency and P2Y14 receptor blockade mitigated DSS-induced colitis. Among the large intestinal immune cells and epithelial cells, eosinophils highly expressed P2ry14 mRNA. P2ry14-/- mice transplanted with wild-type bone marrow eosinophils developed more severe DSS-induced colitis compared with P2ry14-/- mice that received P2ry14-deficient eosinophils. UDP-glucose prolonged the lifespan of eosinophils and promoted gene transcription in the cells through P2Y14 receptor-mediated activation of ERK1/2 signaling. Thus, the UDP-glucose/P2Y14 receptor axis aggravates large intestinal inflammation by accelerating the accumulation and activation of eosinophils.
- 18 December 2023
- Published by Oxford University Press (OUP) in International Immunology
- Vol. 36 (4) , 155-166
The UDP-glucose/P2Y14 receptor axis promotes eosinophil-dependent large intestinal inflammation
Ulcerative colitis (UC) is a chronic disorder of the large intestine with inflammation and ulceration. The incidence and prevalence of UC have been rapidly increasing worldwide, but its etiology remains unknown. In patients with UC, the accumulation of eosinophils in the large intestinal mucosa is associated with increased disease activity. However, the molecular mechanism underlying the promotion of intestinal eosinophilia in patients with UC remains poorly understood. Here, we show that uridine diphosphate (UDP)-glucose mediates the eosinophil-dependent promotion of colonic inflammation via the purinergic receptor P2Y14. The expression of P2RY14 mRNA was upregulated in the large intestinal mucosa of patients with UC. The P2Y14 receptor ligand UDP-glucose was increased in the large intestinal tissue of mice administered dextran sodium sulfate (DSS). In addition, P2ry14 deficiency and P2Y14 receptor blockade mitigated DSS-induced colitis. Among the large intestinal immune cells and epithelial cells, eosinophils highly expressed P2ry14 mRNA. P2ry14-/- mice transplanted with wild-type bone marrow eosinophils developed more severe DSS-induced colitis compared with P2ry14-/- mice that received P2ry14-deficient eosinophils. UDP-glucose prolonged the lifespan of eosinophils and promoted gene transcription in the cells through P2Y14 receptor-mediated activation of ERK1/2 signaling. Thus, the UDP-glucose/P2Y14 receptor axis aggravates large intestinal inflammation by accelerating the accumulation and activation of eosinophils.